Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 15 abstracts from its cystic fibrosis (CF) research and development program will be presented at the 28th Annual North American Cystic Fibrosis Conference (NACFC) in Atlanta, October 9 to 11, 2014. Data from the Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor in people with CF who have two copies of the F508del mutation will be presented, as well as data from other Phase 2 and 3 studies of ivacaftor and of VX-661 in combination with ivacaftor.
Help employers find you! Check out all the jobs and post your resume.
